Finvector Oy Is A Finnish Biopharmaceutical Company Founded In 1993 By Professor Seppo Yli Herttualaheadquartered In Kuopiofinlandthe Company Specializes In The Manufacturing Of Viral Based Gene Therapies And Operates A Cgmp Compliant Facility Recognized As A Global Competence Center In This Fieldfinvector Is Dedicated To Improving The Quality Of Life For Individuals With Chronic Conditions Through Innovative Treatments The Company Focuses On Producing Viral Based Gene Therapy Productswith A Flagship Treatment For Non Muscle Invasive Bladder Cancernmibcthat Has Received International Acclaimfinvector Is Known For Its Expertise In Adeno Associated Virusaavand Lentiviral Vector Productionthe Kuopio Facility Is One Of The Most Modern Gene Therapy Production Sites Worldwidesupported By Significant Investments And Collaborations With The University Of Eastern Finland And Other Regional Partners Finvector S Mission Is To Prioritize Safetyefficacyand Innovation In Gene Therapyemphasizing Scientific Excellence And Collaborationthe Company Is Also Expanding Its Operations To Further Enhance Its Role As A Gene Therapy Hubreflecting Its Commitment To Advancing The Field
